Clinical Trial Update: A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease [Phase 1]

View source ↗

Summary

Phase I study of etrolizumab in pediatric patients with moderate-to-severe ulcerative colitis or Crohn's disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Etrolizumab (etrolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Ulcerative Colitis, Crohn's Disease | Phase 1 | Status: TERMINATED | Results posted: 2020-08-05